sb 203580 has been researched along with dobutamine in 3 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | sb 203580 (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, W; Hu, X; Jiang, H; Wang, J; Xie, J; Xu, W; Yang, H; Zhou, X | 1 |
| Hu, X; Jiang, H; Wang, J; Xie, J; Zhou, X | 1 |
| Hu, X; Jiang, H; Wang, J; Xie, J; Xu, W | 1 |
3 other study(ies) available for sb 203580 and dobutamine
| Article | Year |
|---|---|
Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo.
Topics: Adrenergic beta-1 Receptor Agonists; Animals; Chromones; Disease Models, Animal; Dobutamine; Enzyme Inhibitors; Heart; Heme Oxygenase-1; HMGB1 Protein; Imidazoles; Male; Morpholines; Myocardial Reperfusion Injury; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protoporphyrins; Pyridines; Rats; Rats, Sprague-Dawley | 2013 |
[Selectively stimulating β1-adrenergic receptor attenuates rat myocardial ischemia/reperfusion injury in vivo by inhibiting high mobility group box 1 protein release].
Topics: Animals; Chromones; Dobutamine; HMGB1 Protein; Imidazoles; Interleukin-6; Male; Morpholines; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; NF-kappa B; Oxidative Stress; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic; Reperfusion Injury; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2014 |
Beta-1-adrenergic receptors mediate Nrf2-HO-1-HMGB1 axis regulation to attenuate hypoxia/reoxygenation-induced cardiomyocytes injury in vitro.
Topics: Adrenergic beta-1 Receptor Agonists; Animals; Animals, Newborn; Cell Hypoxia; Cell Survival; Cells, Cultured; Chromones; Dobutamine; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); HMGB1 Protein; Imidazoles; In Vitro Techniques; Morpholines; Myocytes, Cardiac; NF-E2-Related Factor 2; Pyridines; Rats; Receptors, Adrenergic, beta-1 | 2015 |